Lissencephaly due to TUBA1A mutation

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:171680OMIM:611603Q04.3
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Lissencephaly due to TUBA1A mutation (also known as TUBA1A-related lissencephaly or tubulinopathy-related lissencephaly) is a rare congenital brain malformation disorder caused by mutations in the TUBA1A gene, which encodes the alpha-1A tubulin protein. This protein is a critical component of microtubules, which play an essential role in neuronal migration during brain development. When TUBA1A is disrupted, neurons fail to migrate properly to their correct positions in the cerebral cortex, resulting in a smooth or incompletely folded brain surface (lissencephaly) rather than the normal pattern of gyri and sulci. The spectrum of brain malformations can range from classic lissencephaly (agyria-pachygyria) to more complex malformations including cerebellar hypoplasia, corpus callosum dysgenesis, and abnormalities of the hippocampus and basal ganglia. The condition primarily affects the central nervous system and manifests in the neonatal or early infantile period. Key clinical features include severe intellectual disability, intractable epilepsy (often with infantile spasms), significant motor impairment including spastic quadriplegia, microcephaly, and feeding difficulties. Many affected children have limited or absent speech development and require lifelong supportive care. The severity of symptoms generally correlates with the degree of cortical malformation observed on brain MRI. There is currently no cure or disease-modifying treatment for lissencephaly due to TUBA1A mutation. Management is supportive and symptomatic, focusing on seizure control with antiepileptic medications, physical and occupational therapy to optimize motor function, nutritional support (which may include gastrostomy tube placement for feeding difficulties), and management of respiratory complications. A multidisciplinary team approach involving neurologists, geneticists, developmental pediatricians, and rehabilitation specialists is essential for optimizing quality of life.

Clinical phenotype terms— hover any for plain English:

LissencephalyHP:0001339Dilated fourth ventricleHP:0002198Hypoplasia of the brainstemHP:0002365Dysgenesis of the hippocampusHP:0025101Hypoplastic anterior limbs of the internal capsuleHP:0034051Partial agenesis of the corpus callosumHP:0001338Dysplastic corpus callosumHP:0006989
Inheritance

Autosomal dominant

Passed on from just one parent; each child has about a 50% chance of inheriting it

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Lissencephaly due to TUBA1A mutation.

View clinical trials →

No actively recruiting trials found for Lissencephaly due to TUBA1A mutation at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Lissencephaly due to TUBA1A mutation community →

No specialists are currently listed for Lissencephaly due to TUBA1A mutation.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Lissencephaly due to TUBA1A mutation.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Lissencephaly due to TUBA1A mutationForum →

No community posts yet. Be the first to share your experience with Lissencephaly due to TUBA1A mutation.

Start the conversation →

Latest news about Lissencephaly due to TUBA1A mutation

No recent news articles for Lissencephaly due to TUBA1A mutation.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Lissencephaly due to TUBA1A mutation

What is Lissencephaly due to TUBA1A mutation?

Lissencephaly due to TUBA1A mutation (also known as TUBA1A-related lissencephaly or tubulinopathy-related lissencephaly) is a rare congenital brain malformation disorder caused by mutations in the TUBA1A gene, which encodes the alpha-1A tubulin protein. This protein is a critical component of microtubules, which play an essential role in neuronal migration during brain development. When TUBA1A is disrupted, neurons fail to migrate properly to their correct positions in the cerebral cortex, resulting in a smooth or incompletely folded brain surface (lissencephaly) rather than the normal pattern

How is Lissencephaly due to TUBA1A mutation inherited?

Lissencephaly due to TUBA1A mutation follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Lissencephaly due to TUBA1A mutation typically begin?

Typical onset of Lissencephaly due to TUBA1A mutation is neonatal. Age of onset can vary across affected individuals.